Renaissance Capital logo

Pharvaris Priced, Nasdaq: PHVS

Dutch Phase 1 biotech developing oral small molecule therapies for rare diseases.

Industry: Health Care

Latest Trade: $17.44 0.00 (0.0%)

First Day Return: +45.0%

Return from IPO: -12.8%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Our first molecule, PHA121, is a novel, small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema, or HAE. Bradykinin-B2-receptor inhibition is a clinically validated mechanism for the treatment of HAE, as demonstrated by icatibant, which is a bradykinin B2-receptor antagonist approved in Europe in 2008 and in the United States in 2011 (as FIRAZYR). We designed PHA121 to improve upon the therapeutic profile of existing therapies and, through oral delivery, to provide patients with quality of life and convenience that is superior to current standard-of-care HAE treatments, which are injectables. We believe PHA121 has the potential to provide a safe, effective and convenient option for both acute and prophylactic treatments of HAE, in the form of our PHVS416 on-demand rapid exposure product candidate, and for prophylaxis of HAE, in the form of our PHVS719 small daily dose extended-release product candidate. We believe that our product candidates may address a broader range of angioedema attacks than other available treatments since PHA121 blocks the actual signal that leads to angioedema (the interaction of bradykinin, or BK, with the bradykinin B2 receptor), rather than an upstream signal.
more less
IPO News for Pharvaris
more
IPO Data
IPO File Date 01/15/2021
Offer Price $20.00
Price Range $17.00 - $19.00
Offer Shares (mm) 8.3
Deal Size ($mm) $165
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/04/2021
Offer Price $20.00
Price Range $17.00 - $19.00
Offer Shares (mm) 8.3
Deal Size ($mm) $165
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Leiden, Netherlands
Founded 2015
Employees 14
Website www.pharvaris.com